A lack of clear information on COVID risk is stopping people with long-term conditions accessing the care they need – and could be storing up problems for the future.
Eli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found serious quality control problems at the plant, according to press reports.
There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US.
Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-
The spotlight remains on the potential of antibody therapies as a possible way out of the COVID-19 pandemic crisis, with the US government investing millions in a hopeful from AstraZeneca a